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Abstract. Fibroblast growth factor receptor-like 1 (FGFRL1) is 
a transmembrane receptor that interacts with heparin and FGF 
ligands. In contrast to the classical FGF receptors, FGFR1 to 
FGFR4, it does not appear to affect cell growth and prolifera-
tion. In the present study, an inducible gene expression system 
was utilized in combination with a xenograft tumor model to 
investigate the effects of FGFRL1 on cell adhesion and tumor 
formation. It was determined that recombinant FGFRL1 
promotes the adhesion of HEK 293 Tet-On® cells in vitro. 
Moreover, when such cells are induced to express FGFRL1ΔC 
they aggregate into huge clusters. If injected into nude mice, 
the cells form large tumors. Notably, this tumor growth is 
completely inhibited when the expression of FGFRL1 is 
induced. The forced expression of FGFRL1 in the tumor tissue 
may restore contact inhibition, thereby preventing growth of the 
cells in nude mice. The results of the present study demonstrate 
that FGFRL1 acts as a tumor suppressor similar to numerous 
other cell adhesion proteins. It is therefore likely that FGFRL1 
functions as a regular cell-cell adhesion protein.
Introduction
Cell adhesion proteins form connections between individual 
cells and mediate the interactions of cells with the surrounding 
extracellular matrix (ECM) (1). In this way, they participate 
in various cellular functions, including signal transduction, 
communication, embryogenesis, inflammation and apoptosis.
The majority of cell adhesion proteins can be grouped 
into one of five families: The immunoglobulin family, the 
integrins, the cadherins, the selectins and the syndecans (1-3). 
Members of the immunoglobulin family promote cell adhesion 
in a calcium-independent manner. These proteins contain an 
extracellular section with a variable number of immunoglobin 
(Ig)-like domains, a relatively short intracellular domain and a 
single transmembrane domain. For example, cell adhesion mole-
cule-1 (CADM1; also known as nectin-like protein 2) contains 
three extracellular Ig-like domains and binds with its intracel-
lular domain to the adapter protein DAL1, which in turn anchors 
CADM1 to the actin cytoskeleton (1-3). Integrins are involved in 
the integration of the ECM with the cytoskeleton. These proteins 
represent noncovalently linked heterodimers composed of an α 
and a β subunit. The majority of integrins acts as receptors for 
ECM proteins, including fibronectin, vitronectin, collagens and 
laminin, and recognizes the Arg-Gly-Asp sequence within target 
proteins (1-3). Cadherins are calcium-dependent cell adhesion 
molecules. E-cadherin, for example, contains an extracellular 
domain with 5 cadherin repeats, an intracellular domain and 
a transmembrane domain. The intracellular domain interacts 
with catenin and binds to the actin cytoskeleton (1-3). Selectins 
mediate the interactions between leukocytes and endothelial 
cells. They are composed of a single transmembrane domain, 
a short intracellular domain and an extracellular domain with a 
variable number of sushi motifs. Typically, selectins assist with 
the homing of lymphocytes to the lymph node (1-3). Finally, 
syndecans are proteoglycans located on the cell membrane. 
They contain a variable number of glycosaminoglycan chains 
attached to strategic serine residues of the polypeptide chain. 
In addition to mediating cell-matrix and cell-cell interactions, 
syndecans contribute to modulating the activity of heparin 
binding growth factors (1-3).
Evidence from previous studies indicates that cell adhesion 
proteins participate in tumor formation and metastasis (2,3). 
Indeed, the progression of cancer is often associated with 
the loss of at least one cell adhesion protein. However, cell 
adhesion proteins can also function as tumor suppressors 
when overexpressed in tumor tissues (2,3). It appears that their 
forced expression restores contact inhibition, a phenomenon 
observed in normal cells, but not in the majority of malig-
nant cells. E-cadherin, for example, is often lost in tumors 
of epithelial origin and it has been demonstrated that the 
disruption of cell adhesion mediated by E-cadherin is associ-
ated with the development and progression of cancer (4). The 
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forced expression of E-cadherin in tumor cell lines slows 
down cell proliferation and reduces cell invasiveness. By 
contrast, inhibiting E-cadherin using antibodies or antisense 
RNA restores the invasiveness of the cells (4). Likewise, inte-
grin α7 is frequently mutated in human malignancies and such 
mutations are associated with cancer recurrence (5). It has 
been demonstrated that the increased expression of integrin 
α7 in leiomyosarcoma cells resulted in the reduction of colony 
formation. Moreover, increasing the expression of α7 integrin 
in mice with xenografted tumors inhibited tumor growth (5). 
Likewise, CADM1 has been implicated in cancer progression. 
Downregulation of CADM1 synthesis has been observed in a 
variety of human tumors, including breast cancer and esopha-
geal squamous cell carcinoma (6,7). However, it has been 
demonstrated that restoring CADM1 expression suppresses 
cell growth and slows down tumor invasion (7). It has therefore 
been concluded that the majority of the cell adhesion proteins 
can function as tumor suppressors (2,3).
A previous study by our group described a novel trans-
membrane protein that resembles CADM1 (8,9). This protein 
contains three extracellular Ig-like domains, a relatively short 
intracellular domain and a single transmembrane domain. It 
interacts with heparin and fibroblast growth factors (FGFs) 
in a manner similar to the classical FGF receptors (FRFRs), 
FGFR1-FGFR4 (10,11). For this reason, the novel protein was 
termed FGFR-like 1 protein (FGFRL1). However, FGFRL1 
does not possess the intracellular tyrosine kinase domain 
required for signal transduction by transphosphorylation and 
consequently cannot mediate FGF signaling by itself.
The function of the novel receptor is currently unclear. 
Knockout mice with a targeted disruption of the FGFRL1 
gene present a striking phenotype; they lack metanephric 
kidneys (12) and die at birth due to a weak, malformed 
diaphragm that cannot inflate the lungs after birth (13,14). 
Cell culture experiments have demonstrated that FGFRL1 can 
act as a typical cell adhesion protein when coated on plastic 
dishes. FGFRL1 forms heterophilic interactions with heparan 
sulfate proteoglycans, such as glypican, at the cell surface of 
neighboring cells (15). A tetracycline-inducible system has 
been utilized, in which the expression of FGFRL1 could be 
controlled by the addition of the inducer doxycycline (16). It 
was observed that in the presence of doxycycline, cells aggre-
gated and formed huge clusters, whereas in its absence, they 
tended to remain as individual clones (17).
In the present study, one of the tetracycline-inducible cell 
clones was characterized in more detail. The primary aim of 
the study was to determine whether FGFRL1 functions as a 
tumor suppressor in a manner similar to other cell adhesion 
proteins.
Materials and methods
Cell culture. The generation of tetracycline-inducible cell 
clones has been described in detail in a recent publication (17). 
The stable clone K13ΔC was produced by transfection of a 
cDNA for truncated FGFRL1 (corresponding to amino acid 
residues 1-417) into HEK 293 Tet-On® cells (Clontech Labo-
ratories, Takara Bio Europe SAS, Saint-Germain-en-Laye, 
France). The cells were cultivated in an atmosphere of 5% 
CO2 in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin (all Sigma-Aldrich, 
Buchs, Switzerland). To maintain the selective pressure for 
stable transfection, 100 µg/ml Hygromycin B (InvivoGen, San 
Diego, CA, USA) was used. Expression of FGFRL1 from the 
tetracycline responsive promoter was induced by the addition 
of 1 µg/ml doxycycline.
Adhesion experiments. Recombinant FGFRL1 protein was 
isolated from the conditioned media of HEK 293 cells that 
had been stably transfected with a cDNA for human FGFRL1 
(corresponding to amino acid residues 1-357), as previously 
described (18). The recombinant protein was purified by 
chromatography on a column of Heparin Sepharose® 6 Fast 
Flow (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) as 
previously described (18). FGFRL1 protein or bovine serum 
albumin (BSA; Sigma-Aldrich), which served as a control, 
was diluted to 20 µg/ml in phosphate-buffered saline (PBS) 
and droplets of the solution (15 µl) were spotted onto 35-mm 
petri dishes (non-tissue culture; catalog no. 82.1135; Sarstedt 
Co., Nümbrecht, Germany). Following incubation in a 
humidified chamber at 4˚C for 16 h, the solution was carefully 
aspirated and all residual sites of the petri dish were blocked 
with 1% BSA in PBS. Cells were seeded onto pre-coated 
petri dishes in serum-free medium (2x106 cells/plate) and 
incubated for 1 h at 37˚C. Non‑adherent cells were carefully 
removed by washing with PBS. Adherent cells were fixed 
with 4% paraformaldehyde (Sigma-Aldrich) and inspected 
under a microscope (Nikon Eclipse E800; Nikon AG, Zurich, 
Switzerland).
In a further experiment, the cells were cultivated in 
complete growth medium (as aforementioned) on uncoated 
petri dishes (non-tissue culture) for 1-3 days, and cell adhesion 
and cell-cell clustering were documented with a Zeiss Axio-
vert 10 microscope (Carl Zeiss AG, Oberkochen, Germany).
Immunocytochemistry. Cells grown on coverslips were 
washed with ice‑cold PBS, fixed with 4% paraformaldehyde 
and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich) 
in PBS. Non‑specific sites were blocked with 3% BSA in 
PBS. The fixed cells were incubated for 3 h at room tempera-
ture with a humanized monoclonal antibody (1 µg/ml) 
against FGFRL1 that had been prepared by our group in a 
previous study (19). Following three steps of washing with 
PBS, bound antibodies were detected with Cy2-labeled 
secondary antibodies (catalog no. 109-225-097; dilution 
1:200; Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA). The nuclei of the cells were stained with 1 µg/ml 
4',6-diamidino-2-phenylindole (Invitrogen; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). To detect filamentous 
actin, fixed cells were treated in a similar way with tetra-
methylrhodamine-labeled phalloidin (Sigma-Aldrich).
Electron microscopy. Cells grown on cover slips were fixed 
with 2.5% glutaraldehyde in 30 mM potassium phosphate 
buffer. The fixed cells were dehydrated in ethanol, critical 
point dried and sputter-coated with gold, as previously 
described (20). Finally, the specimens were inspected with a 
Philips XL 30 FEG scanning electron microscope operated at 
10 kV (Philips, Amsterdam, The Netherlands).
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Nude mice xenograft experiments. To investigate tumori-
genicity, immunodeficient CD‑1® NU/NU-Foxn1 nude mice 
(Charles River Wiga GmbH, Sulzfeld, Germany) were utilized. 
Approximately 1x107 K13ΔC cells in PBS were subcutane-
ously injected at two ventral sites into the animals. Half of 
the mice (4 mice per group, randomly selected) were treated 
with 100 µg/ml doxycycline, which was directly added to the 
drinking water of the animals; the other half received regular 
water. After 5 weeks, the mice were sacrificed and images of 
the tumors were captured. All animal experiments had been 
approved by the Ethics committee of the County of Bern.
Statistical analysis. The significance of the results from 
the xenograft experiments was analyzed with the exact 
Fisher test utilizing an online calculation tool (http://www.
quantitativeskills.com). P≤0.05 was considered to indicate a 
statistically significant difference.
Results
FGFRL1 overexpression in cell culture. All the following 
experiments were performed with clone K13ΔC from the 
Tet-On-FGFRL1ΔC cell line (17). This clone had been 
prepared with cDNA for FGFRL1, which covered the extracel-
lular domain and the transmembrane helix of the protein, but 
lacked the intracellular domain. Hence, all effects observed 
with this clone may be attributed to the extracellular and the 
transmembrane domains of FGFRL1.
In the absence of doxycycline, the K13ΔC clone did not 
express any detectable FGFRL1ΔC protein, as verified with 
our monoclonal antibodies (Fig. 1A). Following induction 
with doxycycline, a strong signal for FGFRL1 was observed 
at the cell membrane (Fig. 1B). Thus, K13ΔC cells tightly 
controlled the expression of FGFRL1ΔC depending on the 
presence or absence of doxycycline. When the focus of 
the microscope lens was changed to the plane of the glass 
slide (rather than the site of strongest fluorescence), some 
fluorescent signal was observed at numerous protrusions 
that emerged from the plasma membrane of the cells in a 
spike-like fashion (Fig. 1C). To investigate whether these 
microspikes represented normal filopodia, the cells were 
stained with fluorescently labeled phalloidin, which is known 
to interact with filamentous actin. Again, a number of spikes 
was observed that protruded in a perpendicular manner from 
the plasma membrane (Fig. 1D‑F). At higher magnification 
(objective lens, 100X), the FGFRL1ΔC signal (green) partially 
Figure 1. Expression of FGFRL1 in HEK 293 Tet-On-FGFRL1ΔC cells induces the formation of filopodia‑like spikes. FGFRL1‑inducible cells (clone K13ΔC) 
were cultivated in the absence (no Dox) or presence (plus Dox) of the inducer doxycycline. (A-C) Expression of FGFRL1ΔC was visualized with a monoclonal 
antibody against human FGFRL1, followed by Cy2-labeled secondary antibodies (green). FGFRL1ΔC was observed primarily at the cell membrane and in 
microspikes that emerged from the cell membrane. (D-F) Filamentous actin was stained with tetramethylrhodamine-labeled phalloidin (red). (G-I) Merging 
of the pictures stained for FGFRL1 and for actin indicated that the filopodia‑like spikes partially colocalized with filamentous actin. In the absence of 
doxycycline, no FGFRL1ΔC expression was observed and the number of filopodia‑like spikes was much lower. For easy reference, cell nuclei stained with 
4',6‑diamidino‑2‑phenylindole are included in panels A, B, D, and E. FGFRL1, fibroblast growth factor receptor‑like 1; Dox, doxycycline.
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co-localized with the phalloidin signal (red) (Fig. 1G-I). 
Additionally, the spikes were visualized under a scanning 
electron microscope (Fig. 2). Here, numerous protrusions 
were detected that had an average diameter of 180±28 nm 
(n=6). It is therefore likely that the spikes represent regular 
filopodia. Notably, a much larger number of filopodia was 
observed in the presence of doxycycline compared with the 
number observed in its absence (Fig. 1D-F). Thus, forced 
expression of FGFRL1ΔC appears to stimulate the formation 
of filopodia.
Next, it was investigated whether K13ΔC cells would 
bind to purified FGFRL1 protein, as has previously been 
documented in Chinese hamster ovary (CHO) cells (15). 
The surface of a plastic plate (non-tissue culture) was coated 
with droplets of recombinant FGFRL1 solution comprising 
the Ig1-Ig3 domains, or with droplets of BSA that served 
as a control. Within 1 h, the K13ΔC cells attached to the 
recombinant FGFRL1 protein, however, they did not attach 
to the control BSA (Fig. 3). It is likely that this interaction 
was accomplished by the binding of FGFRL1 to cell surface 
heparan sulfate proteoglycans, since the binding could be 
blocked with soluble heparin (data not shown), as previously 
reported in CHO cells (15).
In the following experiment, the effect of doxycycline 
(and therefore the effect of FGFRL1ΔC) on cell-cell adhesion 
and cell clustering was recapitulated (Fig. 4). K13ΔC cells 
formed large patches of 10-30 cells following 9 h of incuba-
tion on bacterial plates in the presence of doxycycline. In the 
absence of the inducer, the cells also started to form clusters, 
however, these clusters were much smaller. After 3 days in 
culture, the K13ΔC cells had merged to form a continuous 
network of cells. Notably, the borders between the indi-
vidual cells were no longer distinguishable in the presence 
of doxycycline, whereas they were clearly detectable in its 
absence. Thus, the presence of FGFRL1ΔC promotes tight, 
intimate interactions between cells. Taken together, the three 
experiments suggested that FGFRL1 represents a typical cell 
adhesion protein.
Xenograft tumor model. The majority of cell adhesion 
proteins can function as tumor suppressors (2,3); therefore, 
the effects of FGFRL1 on tumor formation were investigated. 
K13ΔC cells were injected subcutaneously into immunocom-
promised nude mice at two ventral sites. Half of the mice 
received doxycycline in their drinking water in order to 
induce the expression of FGFRL1ΔC. The other half served 
as controls and received regular drinking water. Within 
5 weeks, the control animals had developed large tumors 
(diameter ≥12 mm) at five out of the eight injection sites 
(Fig. 5). In sharp contrast, none of the doxycycline-treated 
mice had produced any tumors (P=0.0257). A control 
experiment confirmed that doxycycline itself had no effect 
on tumor growth (data not shown). Thus, FGFRL1 may func-
tion as a typical tumor suppressor that effectively inhibits the 
outgrowth of xenografted tumors in vivo.
Figure 3. FGFRL1 induces cell adhesion. Droplets of a solution of recom-
binant FGFRL1 (or of BSA, which acted as a control) were spotted onto 
bacterial petri dishes and incubated overnight at 4˚C in a humidified 
chamber. Residual binding sites of the plastic surface were blocked with 
BSA. HEK 293 Tet-On-FGFRL1ΔC cells (clone K13ΔC) were seeded onto 
the pre-coated dishes and allowed to attach for 1 h. Non-adherent cells were 
washed off; adherent cells were fixed. FGFRL1 promoted cell attachment, 
whereas BSA (indicated by the dotted circle) did not. FGFRL1, fibroblast 
growth factor receptor-like 1; BSA, bovine serum albumin.
Figure 2. Electron microscopy of HEK 293 Tet-On-FGFRL1ΔC cells. Clone 
K13ΔC was cultivated in the presence of doxycycline, fixed with glutaralde-
hyde and prepared for SEM. Inspection by SEM at 10 kV detected numerous 
filopodia‑like spikes with a diameter of ~200 nm. Bar, 5 µm. SEM, scanning 
electron microscopy.
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Discussion
The current study, taken together with results from the litera-
ture, demonstrates that the novel receptor FGFRL1 represents 
a regular cell-cell adhesion protein. This conclusion is based 
on the following facts: i) The domain structure of FGFRL1, 
which has a single transmembrane domain, three extracel-
lular Ig-like repeats and a short intracellular domain (21), 
resembles the structure of other cell adhesion proteins from 
the Ig superfamily, namely the nectins and nectin-like mole-
cules (22,23). ii) Recombinant polypeptides corresponding to 
the extracellular domain of FGFRL1 promote cell adhesion 
in vitro. If a mutation is introduced into the polypeptide chain, 
the activity is completely lost (15). iii) When overexpressed in 
different cell lines, FGFRL1 protein accumulates at intersec-
tions where two cells touch each other (15). Overexpression 
in HEK 293 Tet-On cells leads to the aggregation of the cells 
and to the formation of large clusters (17). iv) Finally, the 
results of the current study indicate that FGFRL1, like other 
typical cell adhesion proteins, acts as a tumor suppressor in 
a xenograft tumor model. It was determined that the forced 
expression of FGFRL1 in HEK 293 Tet-On cells completely 
inhibited the outgrowth of tumors in immunocompromised 
mice.
During the xenograft experiments, it was noted that the 
cells were not extremely tumorigenic. A large number of HEK 
293 Tet-On-FGFRL1ΔC cells had to be injected into the mice 
to initiate any tumor growth. Other studies have also noted 
that HEK 293 cells exhibit particularly low tumorigenicity. 
Shen et al (24) demonstrated that HEK 293 cell tumorigenicity 
increased with increasing passage number, and finally reached 
100% when the passage number was >65; however, the original 
Figure 4. FGFRL1 induces cell-cell adhesion and cell clustering. FGFRL1-inducible HEK 293 Tet-On cells (clone K13ΔC) were seeded into bacterial petri 
dishes and cultivated for up to 3 days in the absence (no Dox) or presence (plus Dox) of doxycycline. Expression of FGFRL1ΔC induced cell-cell adhesion and 
cell clustering. After 3 days, the boundaries between cells were barely detectable in the presence of doxycycline, whereas they were clearly detectable in its 
absence. FGFRL1, fibroblast growth factor receptor‑like 1; Dox, doxycycline.
Figure 5. FGFRL1 acts as a tumor suppressor in vivo. Inducible HEK 293 Tet-On-FGFRL1ΔC cells (clone K13ΔC) were injected into nude mice at two ventral 
positions. Expression of FGFRL1 was induced in half of the animals by doxycycline, which was added to their drinking water. The other half received normal 
drinking water. Tumor formation was inspected at the injection sites after 5 weeks. Two representative examples of each group are depicted. The injected cells 
were able to generate tumors only in those mice that did not receive any doxycycline. FGFRL1, fibroblast growth factor receptor‑like 1; Dox, doxycycline.
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isolates of the cells did not form tumors at all in nude mice. 
In the present study, an outgrowth of tumors was detected in 
the absence of doxycycline in 5 cases (63%). Following induc-
tion of FGFRL1 synthesis, tumor growth was observed in no 
cases (0%). Doxycycline itself had no effect on tumor growth, 
as demonstrated in a control experiment and as previously 
published in the literature (25). Thus, it is FGFRL1 that can act 
as a tumor suppressor.
Previous studies have reported that alterations in the 
synthesis of FGFRL1 occur in tumor cells (26-31). The 
screening of 241 different human tumor samples with a 
cancer‑profiling array suggested that major changes in the 
relative expression of FGFRL1 occur in ovarian tumors (26). 
In several samples, a significant decrease in FGFRL1 expres-
sion was observed in the tumor tissue relative to the matched 
control tissue. However, in one ovarian tumor sample there 
was a 25-fold increase (26). Furthermore, the overexpression 
of FGFRL1 in certain ovarian tumor samples was confirmed 
in a study aiming to identify novel tumor-specific marker 
genes (27). An association of FGFRL1 expression with 
tumor growth and metastasis was also suggested by a study 
of patients suffering from head and neck tumors (28,29). In 
this case, FGFRL1 overexpression appeared to correlate with 
tumor growth. Another study noted a significant decrease of 
FGFRL1 protein expression in bladder tumors and bladder 
cancer cell lines (30). This decrease was explained by hetero-
zygous deletions at the chromosomal region 4p16.3, which 
includes the locus of the FGFRL1 gene. Finally, mutations 
affecting the reading frame of FGFRL1 have been observed 
relatively frequently in colorectal cancer cell lines (31). The 
majority of these mutations occurred in the intracellular 
domain of the protein.
The molecular mechanism governing how FGFRL1 may 
inhibit tumor growth in a xenograft model is complex. With 
other cell adhesion proteins it has been concluded that forced 
expression partially restores contact inhibition of the tumor 
cells. In the case of CADM1, it was demonstrated that homo-
philic interactions of CADM1 at the surface of two adjacent cells 
activated the phosphatidylinositol 3-kinase (PI3K) pathway 
and led to the reorganization of the actin cytoskeleton (32). 
The intracellular domain of CADM1 formed a complex with 
membrane-associated guanylate kinase homologues, including 
MPP3 and Dlg, thus linking CADM1 and PI3K. In the case of 
FGFRL1, the effect may be exerted by heterophilic interac-
tions of the extracellular domain of FGFRL1 with another 
transmembrane protein, since the protein expressed by K13ΔC 
cells lacks the intracellular domain of FGFRL1. The extracel-
lular domain has the ability to interact with target proteins of 
neighboring cells containing heparan sulfate chains, including 
syndecans and glypicans (15). Two target proteins, glypican-4 
and glypican-6, which specifically interact with FGFRL1, 
have previously been identified by our group using tandem 
LC mass spectrometry (16). Therefore, it is hypothesized that 
FGFRL1 inhibited tumor growth in the current study in the 
following manner: HEK 293 Tet-On cells lost their normal 
contact inhibition and grew in an unrestricted way, as they 
were subcloned multiple times during the generation of the 
HEK 293 Tet-On-FGFRL1ΔC clones. When injected into nude 
mice, these cells gave rise to large tumors due to a defect in 
contact inhibition. Enforcing the expression of FGFRL1ΔC in 
the injected cells by adding doxycycline induced the adhesion 
of the cells with each other and restored contact inhibition, 
thereby inhibiting tumor growth.
It remains to be demonstrated whether the identification of 
FGFRL1 as a tumor suppressor may be exploited to improve 
the diagnosis and therapy of cancer patients. FGFRL1 may 
serve as a tumor marker to identify aggressive tumors that 
have lost FGFRL1 expression (27,31). Furthermore, there 
may be the possibility of enhancing FGFRL1 synthesis in 
the tumor tissue. Levels of FGFRL1 mRNA are regulated by 
microRNA-120 (28,33), which specifically interacts with the 
3' end of the FGFRL1 mRNA and leads to its degradation. 
Therefore, if it were possible to downregulate microRNA-120 
expression in the tumor tissue, the endogenous levels of FGFRL1 
would increase and contact inhibition of the cells in the tumor 
tissue would be restored, thus suppressing tumor growth. Future 
studies are necessary to determine whether this could be devel-
oped as a novel therapeutic strategy for patients with cancer.
In conclusion, the current study taken together with results 
from the literature, demonstrates that FGFRL1 is a cell-cell 
adhesion protein that acts as a tumor suppressor similar to 
numerous other cell adhesion proteins.
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